Gene Solutions Showcases Advances in MRD and Multi-Omics in Singapore

At the Singapore Society of Oncology Annual Scientific Meeting 2025, held on October 15, 2025, Gene Solutions presented groundbreaking advancements in Molecular Residual Disease (MRD) and multi-omics technologies aimed at enhancing precision oncology. The event highlighted Singapore’s pivotal role in fostering innovation and collaboration across the Asia-Pacific region in cancer care.

The symposium, titled “Advancing Precision Oncology: MRD and Multi-Omics in Solid Tumors,” brought together leading oncologists and experts in molecular biology to discuss how circulating tumor DNA (ctDNA) and multi-omics analyses can support clinicians and researchers in more accurately monitoring and treating cancer.

Key Insights into MRD and Multi-Omics

MRD assays focus on analyzing ctDNA present in the blood, allowing for real-time monitoring of cancer at the molecular level. During the discussions, experts underscored the potential of this innovative approach to enhance early detection of cancer recurrence and to inform treatment decisions.

Gene Solutions distinguishes itself through its advanced platform that integrates DNA, RNA, and AI-enhanced multi-omics signals. This comprehensive tumor profiling method improves the sensitivity of ctDNA detection, enables the identification of complex gene fusions, and assists in predicting primary tumor locations. Such capabilities pave the way for more personalized and informed treatment strategies.

Recent studies published in JCO Oncology Advances and npj Breast Cancer corroborate the efficacy of ctDNA-based MRD testing, showing promise in predicting early recurrence and facilitating cost-effective monitoring strategies in practical settings.

Call for Collaboration in Precision Oncology

Ida Deleskog Lindstroem, Global Medical Affairs Director at Gene Solutions, emphasized the importance of collaboration in advancing these technologies. “Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively,” she stated. Lindstroem encouraged oncologists, researchers, and healthcare professionals across the Asia-Pacific to join efforts in developing data-driven, personalized care aimed at improving patient outcomes.

With a CAP-accredited laboratory based in Singapore and a robust global operations network, Gene Solutions is committed to fostering scientific collaboration. The company aims to propel genomic research and precision oncology initiatives throughout the region.

Founded as a multinational biotechnology entity, Gene Solutions leverages Next-Generation Sequencing (NGS) and Artificial Intelligence (AI) to provide an extensive range of advanced genetic testing solutions. Having delivered over two million genetic tests, Gene Solutions is recognized for its proprietary research and contributions to the field of precision medicine through clinical studies and regional partnerships.

The discussions at SSO ASM 2025 reflect a growing commitment to innovation in oncology, with a focus on enhancing patient care through technology and collaboration.